Rheumatoid Arthritis Market Sees Increase in Treatment Options, States Roots Analysis in Its Report Published at MarketPublishers.com
19 Dec 2016 • by Natalie Aster
LONDON – The rheumatoid arthritis (RA) market is chiefly populated by disease-modifying anti-rheumatic drugs (DMARDs) that appear to have changed the development of the disease and also enhance roentgenographic outcomes. Biologic DMARDs encompassing TNF inhibitors, like Enbrel®, HUMIRA® and REMICADE®, are amongst the fastest-selling drugs in the marketplace. In the recent past, medical treatment types for RA have increased considerably with the development of a number of new drugs and/or drug classes. Besides B-cell depleting agents, TNF inhibitors, several novel biologic DMARDs, like T-cell costimulatory blocking agents, interleukin-6 (IL-6) inhibitors and interleukin-1 (IL-1) receptor antagonists, have gained FDA approval during the last several years.
Leading biopharma market players, such as BMS, Amgen, Pfizer and Roche/Genentech, presently capture the lion’s share in the total market having the maximum number of marketed drug products in the market space. A number of medium- and large-sized enterprises, encompassing AbbVie, Gilead Sciences, Amgen, Galapagos, GSK, Eli Lilly, Incyte Corporation, Daiichi Sankyo, Janssen, and Sanofi-Aventis, which have RA therapies in late-stage development. Furthermore, there are small-sized players, such as Asana BioSciences, CASI Pharmaceuticals, Avexxin, SBI Biotech, CJ HealthCare, Oscotec, RedHill Biopharma, Peptinov and Toleranzia, that have captured a considerable share of the pre-clinical and/or discovery pipeline.
With a view to addressing the rising concerns pertaining to patient compliance, drug development firms have shifted their attention towards the development of orally administrable drug products. Among all the molecules in pipeline, more than 50% are being developed for oral administration.
In-demand research report “Rheumatoid Arthritis: Beyond TNF Inhibitors, 2016 - 2026” created by Roots Analysis provides a deep analysis of the present-day market landscape of RA based therapies as well as forecasts the sector’s development over the next 10 years.
The study offers a brief review of the disease, limelighting all related complications and symptoms, includes a granular classification and review of MoA of the different therapeutic interventions, etc. It gives a comprehensive assessment of the present-day landscape of the RA marketplace, giving details about more than 80 molecules falling under non-TNF inhibitor drug classes. The report gives a brief introduction to the new interventions presently being investigated as prospective treatment options for the disease. The report encompasses granular profiles of the recently approved and late-stage JAK inhibitors; includes extensive profiles of late-stage anti-ILs. The study encompasses detailed profiles of late-stage drugs/therapies with novel MoA. It includes a shrewd analysis on the forecasted future size of the market for RA therapies in the offing. The report gives certain key insights into RA therapies; presents an analysis on the agreements and partnerships established between market players in the recent past. It sheds light on the emerging trends on social media associated with RA drugs; includes the listing of firms and organisations; and more.
More in-demand studies by Roots Analysis are available at its page.